SCHEMBL10447516

SCHEMBL10447516

O=S(=O)(NCCc1ccccc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.70
PRMT1 Q99873 2/20 0.66
HSD17B10 Q99714 1/20 0.66
CYP19A1 P11511 1/20 0.62
TDP1 Q9NUW8 1/20 0.61
ALDH1A1 P00352 7/20 0.61
MAPT P10636 2/20 0.61
POLB P06746 1/20 0.61
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
LMNA P02545 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
GAA P10253 2/20 0.56
TP53 P04637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287345 0.91 ALDH1A1 (0.72) TAAR1PRMT1HSD17B10CYP19A1TDP1
SCHEMBL5185902 0.85 ALDH1A1 (0.56) TAAR1PRMT1HSD17B10CYP19A1TDP1
SCHEMBL12042482 0.85 ALDH1A1 (0.74) TAAR1PRMT1HSD17B10TDP1ALDH1A1
SCHEMBL9660601 0.85 TBXA2R (0.70) TAAR1CYP19A1TDP1ALDH1A1MAPT
SCHEMBL1954496 0.84 CYP19A1 (0.80) CYP19A1ALDH1A1POLBCA1CA2
SCHEMBL13073727 0.84 ALDH1A1 (0.64) TAAR1PRMT1HSD17B10TDP1ALDH1A1
SCHEMBL412302 0.84 ALDH1A1 (0.79) TAAR1PRMT1HSD17B10TDP1ALDH1A1
SCHEMBL13073499 0.83 TAAR1 (1.00) TAAR1PRMT1HSD17B10TDP1ALDH1A1
Hydrochloric Acid SCHEMBL3517769 0.82 ALDH1A1 (0.77) TAAR1PRMT1HSD17B10TDP1ALDH1A1
SCHEMBL2413993 0.81 HDAC6 (0.58) PRMT1TDP1ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292269-A1 BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2010-11-18 US disclosed
EP-0356989-A2 Sulfon amides with a tetrazolyl rest, process for their preparation an therapeutic agents Roche Diagnostics GmbH (DE) 1990-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292269-A1 BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC3, BIRC2 TAAR1 2301/4885PRMT1 309/4885HSD17B10 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.